Rating Change
Guggenheim analysts reiterated a Buy rating on UroGen Pharma Ltd. (NASDAQ:URGN) on July 21, 2026.
reiterateNASDAQ:URGN
Guggenheim Reiterates Buy Rating on UroGen Pharma Ltd. (URGN)
Rating Change Guggenheim analysts reiterated a Buy rating on UroGen Pharma Ltd. (NASDAQ:URGN) on July 21, 2026. Market Context UroGen Pharma Ltd.
Market Context
UroGen Pharma Ltd. operates in the Healthcare sector. The stock currently trades at $43.78 with a market capitalization of $1.0B. The stock has gained 186.7% over the past 52 weeks.
Analyst coverage from Guggenheim provides professional research and price targets that many institutional investors reference when making allocation decisions. The consensus of analyst opinions — along with the range of price targets — helps frame market expectations for UroGen Pharma Ltd..
Analyst ratings and price targets are one input among many for investment decisions. Historical studies show that consensus analyst recommendations have mixed predictive power on their own, but significant changes in consensus — such as multiple upgrades or downgrades in a short period — can be more meaningful signals.
Recent Analyst Activity for UroGen Pharma Ltd.
Among the 10 most recent ratings: 10 Buy, 0 Hold, 0 Sell.
| Date | Firm | Rating | Price Target |
|---|---|---|---|
| Jul 21, 2026 | Guggenheim | Buy | N/A |
| Jul 16, 2026 | Oppenheimer | Outperformer | N/A |
| Jun 03, 2026 | HC Wainwright & Co. | Buy | N/A |
| May 18, 2026 | HC Wainwright & Co. | Buy | N/A |
| May 11, 2026 | HC Wainwright & Co. | Buy | N/A |
Related Tools: Analyst Ratings Dashboard | View URGN Stock Page
Frequently Asked Questions
What does a Buy rating mean for URGN?
A Buy rating from Guggenheim reflects the analyst's outlook on UroGen Pharma Ltd. (NASDAQ:URGN). Analyst ratings are one factor investors consider alongside earnings, valuation, and sector trends.
Where can I find more analyst ratings?
Browse recent upgrades and downgrades on our Analyst Ratings Dashboard or the URGN forecast page.
